p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

NCT03268382 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

High-grade Serous Ovarian Cancer

Interventions

DRUG: APR-246
DRUG: Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

Sponsor

Aprea Therapeutics